Exscientia Ltd., of Oxford, U.K., an artificial intelligence-driven drug discovery company, said it entered a collaboration with Rallybio Inc., of Farmington, Conn., to accelerate the discovery of small-molecule drug therapeutics for undisclosed rare disease indications.